21-09-11

Ateneo Central 21 de Septiembre de 2011

Datos personales ,[object Object],[object Object]

Factores de Riesgo ,[object Object],[object Object],[object Object]

Medicación habitual ,[object Object],[object Object]

Enfermedad Actual ,[object Object],[object Object]

SPECT ,[object Object],[object Object],[object Object],[object Object]

Coronariografía ,[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object]

Angioplastía ,[object Object]

[object Object],DEFER STUDY: 5-YEAR FOLLOW-UP

The DEFER Study: Design Prospective randomized multicentric trial (14 centers) in 325 patients with stable chest pain and an intermediate stenosis without objective evidence of ischemia Aalst Amsterdam Eindhoven Essen Gothenborg Hamburg Liège Maastricht Madrid Osaka Rotterdam Seoul Utrecht Zwolle data collection & analysis: Jan Willem Bech, MD, PhD Pepijn van Schaardenburgh, MD

The DEFER Study: Objectivos ,[object Object],[object Object],[object Object],[object Object]

DEFER Group REFERENCE Group PERFORM Group Patients scheduled for PCI without Proof of Ischemia (n=325) performance of PTCA (158) FFR  0.75 (91) No PTCA FFR  0.75 (90) PTCA FFR < 0.75 (76) PTCA Randomization deferral of PTCA (167) FFR < 0.75 (68) PTCA

The DEFER Study: Baseline data Randomized to Randomized to Deferral of PTCA Performance of PTCA N=167 N=158 Age, (yr) 62  9 63  10 Female sex (%) 29 29 Ejection Fraction (%) 67  10 68  9 Diabetes (%) 13 12 Hypertension (%) 41 35 Hyperlipidemia (%) 47 48 Current Smoker (%) 30 25 Family History CAD (%) 50 49

78.8 72.7 64.4 0 1 2 3 4 5 0 25 50 75 100 Defer Perform Reference (FFR < 0.75) p=0.52 p=0.17 p=0.03 Years of Follow-up event – free survival (%) 88 90 96 103 105 135 Reference gr 65 67 70 73 78 88 Perform group 72 73 74 82 85 90 Defer group No. at risk

Cardiac Death And Acute MI After 5 Years 3.3 7.9 15.7 0 5 10 15 20 % P=0.20 P< 0.03 P< 0.005 DEFER PERFORM REFERENCE FFR > 0.75 FFR < 0.75

[object Object],[object Object],[object Object]

FAME Study (Resultados 2 años)

[object Object],FAME Study (Conclusiones)

Functional SYNTAX Score for Risk Assessment in Multivessel Coronary Artery Disease Chang-Wook Nam, MD, PhD*,, Fabio Mangiacapra, MD, Robert Entjes, MD, In-Sung Chung, MD, PhD, Jan-Willem Sels, MD, Pim A.L. Tonino, MD, PhD, Bernard De Bruyne, MD, PhD, Nico H.J. Pijls, MD, PhD, William F. Fearon, MD*,* FAME Study Investigators * Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California Division of Cardiology, Keimyung University Dongsan Medical Center, Daegu, Korea Cardiovascular Center Aalst, Aalst, Belgium Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands Manuscript received February 9, 2011; revised manuscript received June 2, 2011, accepted June 14, 2011. ,[object Object]

Functional SYNTAX Score for Risk Assessment in Multivessel Coronary Artery Disease ,[object Object],[object Object],[object Object]

Functional SYNTAX Score for Risk Assessment in Multivessel Coronary Artery Disease

Validation of Intravascular Ultrasound–Derived Parameters With Fractional Flow Reserve for Assessment of Coronary Stenosis Severity Soo-Jin Kang , MD, PhD, Jong-Young Lee , MD, Jung-Min Ahn , MD, Gary S. Mintz , MD, Won-Jang Kim , MD, Duk-Woo Park , MD, PhD, Sung-Cheol Yun , PhD, Seung-Whan Lee , MD, PhD, Young-Hak Kim , MD, PhD, Cheol Whan Lee , MD, PhD, Seong-Wook Park , MD, PhD and Seung-Jung Park , MD, PhD From the Department of Cardiology (S.-J.K., J.-Y.L., J.-M.A., W.-J.K., D.-W.P., S.-W.L., Y.-H.K., C.W.L., S.-W.P., S.-J.P.) and the Department of Biostatistics (S.-C.Y.), University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; and the Cardiovascular Research Foundation (G.S.M.), New York, NY. ,[object Object],[object Object]

21-09-11

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Destacado

Destacado (7)

Similar a 21-09-11

Similar a 21-09-11 (20)

Más de nachirc

Más de nachirc (20)

21-09-11

Notas del editor